A U.S. judge set aside a jury verdict that found Amgen Inc. patents on the company’s cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc. and Sanofi SA, which sell rival drug Praluent.
The Medicines Company’s inclisiran hit the primary and secondary endpoints in a Phase III trial to decrease LDL cholesterol through twice-a-year dosing.
Regeneron Pharmaceuticals announced positive results from the company’s pivotal Phase III clinical trial of evinacumab in homozygous familial hypercholesterolemia (HoFH).
People who do not consistently get the same amount of sleep or go to bed at the same time each night may be more likely to develop health problems like obesity, high blood pressure, high cholesterol and diabetes, a recent study suggests.
Amarin Corp. provided an update, noting that the company is increasing revenue guidance for 2019 and is planning to expand the sales force for Vascepa due to faster-than-expected growth.
In veteran drug salesman Paul Hudson, Sanofi’s 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.
Germany’s highest civil court rejected French drugmaker Sanofi’s bid to fend off a legal challenge by U.S. rival Amgen against Sanofi’s cholesterol drug Praluent.
High cholesterol is associated with an increased risk of developing glaucoma, but a new study suggests taking statins to lower cholesterol helps to reduce this risk.
Akcea Therapeutics Inc. and Ionis Pharmaceuticals Inc. announced that Waylivra received conditional marketing authorization from the European Commission as the only therapy for FCS.
The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!
